Checkpoint Therapeutics Announces Completion of Enrollment in the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma May 12, 2021
Mustang Bio Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T Therapy May 10, 2021
Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and Europe May 10, 2021
Checkpoint Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Highlights May 06, 2021
Mustang Bio to Participate in Chardan’s 5th Annual Genetic Medicines Manufacturing Summit Apr 21, 2021
Avenue Therapeutics Announces that the FDA is Still Reviewing Its NDA Resubmission for IV Tramadol Apr 13, 2021
Fortress Biotech to Participate in the 20th Annual Needham Virtual Healthcare Conference Apr 07, 2021
Journey Medical Corporation Enters $7.5 Million Line of Credit Agreement with East West Bank Apr 05, 2021
Journey Medical Corporation Enters into a Definitive Agreement with Dermira, Inc., a Wholly-Owned Subsidiary of Eli Lilly and Company, to Acquire QBREXZA® Apr 01, 2021
